Kornimate/medical-research-clean huggingface dataset:
ga levonorgestrel intrauterine contraceptive system (lcs) phase iii study china

Conditions: Contraception

Summary: the purpose of this study is to assess the efficacy, safety, bleeding pattern of low dose lng (12 mg/ 24 hrs), delivered locally by a new intrauterine contraceptive system suitable for use by women 18 to 40 years of age. in addition, pharmacokinetic assessments will be performed.


Eligibility criteria:
inclusion criteria: * has, in the opinion of the investigator, suitable general and uterine conditions for inserting the lcs. * normal cervical smear (normal cervical smear within the last six months prior to visit 1 presented in writing can be accepted. the cervical smear should be analyzed and reported according to the bethesda system.) * has clinically normal safety laboratory results (i.e., inside the specified range for inclusion). * has regular menstrual cycles (length of cycle 21-35 days) (i.e., endogenous cyclicity without hormonal contraceptive use). exclusion criteria: * known or suspected pregnancy or is lactating. * vaginal delivery, cesarean delivery, or abortion within 6 weeks prior to visit 2. note: postpartum insertions should be postponed until uterus is fully involuted, however not earlier than 6 weeks after delivery. if involution is substantially delayed, consider waiting until 12 weeks postpartum. in case of a difficult insertion and/or exceptional pain or bleeding during or after insertion, physical examination and ultrasound should be performed immediately to exclude perforation. * history of ectopic pregnancies. note: for korea only: history of ectopic pregnancies or high probability of ectopic gestation. * infected abortion within 3 months prior to visit 1. note: for korea only: endometritis after delivery or infected abortion within 3 months prior to visit 1. * abnormal uterine bleeding of unknown origin. * any genital infection (until successfully treated). * history of, or current, pelvic inflammatory disease * congenital or acquired uterine anomaly. * any distortion of the uterine cavity (by e.g., fibroids) likely to cause problems (in the opinion of the investigator) during insertion, retention or removal of the lcs. * history of, diagnosed or suspected genital malignancy, and untreated cervical dysplasia. * current deep venous thrombosis or thrombophlebitis; history of deep venous thrombosis. * clinically significant endometrial polyp(s), which, in the opinion of the investigator, will interfere with the assessment of the bleeding profile during the study * clinically significant ovarian cyst(s) * use of any long-acting injectable sex-hormone preparations within 12 months prior to start of study medication, and if entering subset: any sex-hormone administration within one month prior to start of the study medication.

Keywords: contraception intrauterine contraception system
arresting active dentine lesions and quality of life among a group of preschool children

Conditions: Caries Arrest

Summary: testing 3 different caries arresting techniques and the quality of life of a group of preschool children in mansoura city, egypt.

135 preschoolers were allocated randomly into 3 groups to receive 3 techniques to evaluate caries arrestment. the first group received 38% silver diamine fluoride, the second received conventional atraumatic restorative technique and the third group received ultra consevative treatment (uct). the subjects were followed up at 3, 6 and 12 months to check caries activity according to the icdas. the parents of the children answered the arabic ecohis before treatment and after 3 months to assess oral health related quality of life.

Eligibility criteria:
inclusion criteria: * healthy children aged 3-5 * residents of mansoura city * having at least one carious dentine lesion exclusion criteria: * large carious lesions approximating the pulp * signs of pulpitis, fistula, abscess.
study of ace-86225106 to treat patients with advanced solid tumors

Conditions: Solid Tumor, Adult; BRCA1 Mutation; BRCA2 Mutation; Ovarian Cancer; Breast Cancer; Prostate Cancer

Summary: the purpose of this study is to determine if the experimental treatment with poly-adp ribose polymerase (parp) inhibitor, ace-86225106 is safe, tolerable and has anti-cancer activity in adult patients with advanced solid tumors.

this study is a phase i/ii, open-label, multicentre study of ace-86225106 administered orally in patients with advanced solid tumors.

Eligibility criteria:
inclusion criteria: 1. provide written informed consent; 2. advanced solid tumors, difficult to treat or intolerant to standard treatment, suitable for investigational treatment; 3. has eastern cooperative oncology group (ecog) performance status of 0 or 1; 4. has a life expectancy of at least 3 months; 5. has measurable disease per recist 1.1, castration-resistant prostate ccancer (crpc) patients can be assessed according to pcwg3; 6. adequate organ function and bone marrow function; 7. can provide tumor specimens and blood samples for homologous recombination deficiency (hrd)/ homologous recombination repair (hrr) related gene testing. exclusion criteria: 1. receiving any anti-cancer drugs, major surgery, extensive radiation therapy, or local radiation therapy within protocol-defined wash-out period; 2. concomitant use of medications or herbal supplements known to be strong or moderate inhibitors or inducers of cytochrome p450 3a4 (cyp3a4); 3. receiving continuous corticosteroid treatment with a dose of prednisone greater than 10 mg/day or an equivalent dose. 4. receiving continuous treatment with prednisone at a dose of \>10 mg/d or other corticosteroids at an equivalent dose for any reason. 5. any previous treatment-related toxicities have not recovered, i.e., to ≤ grade 1 (as evaluated by nci-ctcae v5), except alopecia and other grade 2 toxicities that are deemed not to affect the conduct of the study, as assessed by the sponsor and the clinical investigator. 6. spinal cord compression or brain metastases unless asymptomatic, treated and stable. 7. severe cardiovascular disorders. 8. myelodysplastic syndrome (mds)/acute myeloid leukemia (aml) or with evidence suggesting possible mds/aml. 9. concomitant diseases or conditions that would preclude the absorption of the investigational product. 10. active infections, or a known history of hiv infection, or a known active hepatitis b or c, or a known active tuberculosis. 11. other malignancies that require treatment within 3 years prior to first dose of study investigational product. 12. conditions with rapid deterioration during the screening period. 13. known allergy or hypersensitivity to the investigational product or any of the excipients of the investigational product. 14. has other medical conditions that at the discretion of investigator interfere with safety or efficacy evaluation, or affect treatment compliance.

Keywords: ace-86225106 advanced solid tumors parp inhibitor brca mutation breast cancer ovarian cancer crpc
sublobar resection versus lobectomy for ct1n0m0 non-small-cell lung cancer

Conditions: Carcinoma, Non-Small-Cell Lung

Summary: the incidence rate of ground-glass opacity (ggo) has been increasing these years. a great number of retrospective studies suggested that sublobar resection was better for some ggo patients. however, no prospective clinical study supports the perspective. this study is prospective, multi-center, randomized-controlled. the aim of this study is to investigate whether sublobar resection is inferior to lobectomy for ct1n0m0 non-small-cell lung cancer or not.


Eligibility criteria:
inclusion criteria: * ct1n0m0 non-small-cell lung cancer * ground-glass opacity, ≤2cm, ggo≥25% * eligible for both lobectomy and sublobar resection * intraoperative pathology is minimally-invasive adenocarcinoma or invasive adenocarcinoma * intraoperative pathology of biopsied station 10 lymph node is negative exclusion criteria: * intraoperative pathology is benign nodule, atypical adenomatous hyperplasia, or adenocarcinoma in-situ * intraoperative pathology of biopsied station 10 lymph node is positive * multiple ggos, lesions other than dominant lesion are malignant or \>5mm * history of thoracic surgery * history of malignancy in recent 5 years * unstable systemic disease * patients with psychiatric disorders

Keywords: sublobar resection lobectomy
study of topical abi-1968 in subjects with precancerous anal lesions resulting from human papillomavirus (hpv) infection

Conditions: HSIL, High-Grade Squamous Intraepithelial Lesions; Human Papilloma Virus Infection; HIV Infection; Anal Cancer; Anus Neoplasm

Summary: this study evaluates the use of abi-1968, a topical cream, in the treatment of anal precancerous lesions in adults with and without human immunodeficiency virus (hiv) infection


Eligibility criteria:
inclusion criteria 1. female or male subjects, at least 27 years old. 2. confirmed diagnosis of intra-anal hsil at least 3 months prior to screening and confirmed by histopathology (with p16 positive staining) 3. intra-anal hsil are visible and evaluable by hra at the time of screening, and no lesion(s) is suspicious for invasive cancer. 4. for hiv-positive subjects, cd4 count must be at least 200/mm3 with undetectable (\<50 copies/ml) viral load within the 3 months prior to enrollment. subjects must be on a stable regimen of antiretroviral drugs for the 3 months prior to enrollment. exclusion criteria: 1. women who are pregnant, plan to become pregnant in the next 3 months, or lactating females. 2. received topical treatment or ablative procedures for ahsil in the 6 months prior to enrolment. 3. history of cancer involving the anogenital region, or history of other cancers that have not been fully resolved and free of symptoms in the past 5 years 4. history of genital herpes with \> 3 outbreaks per year. 5. plan to have excision or ablation of the lesion(s) within 3 months of enrolment.
evaluation of 4d-contrast enhanced pet-ct in tumour volume definition

Conditions: Lung Carcinoma; Lower Oesophageal Carcinoma; Pancreatic Carcinoma

Summary: the aim of high dose radiotherapy treatment is to deliver enough radiation to the tumour to kill all the cancer cells while at the same time giving a low dose of radiation to the normal parts of the body to reduce the side effects of treatment. this requires the cancer specialist to accurately identify the areas of cancer on a computed tomography (ct) scan. positron emission tomography computed tomography (petct) scans use radioactive sugar that is injected into the patient. this sugar goes into cancer cells and shows up as a bright spot on the pet scan, allowing the doctors to see tumours more accurately. some cancers move with breathing, for example lung, pancreas and oesophageal (or gullet) cancers. fourdimensional ct scanning (4dct) is a special type of ct scan that allows the motion of the tumour to be seen and measured accurately. this information can then be used to help ensure that the radiotherapy correctly treats the moving tumour. the aim of this study is to see if there are possible benefits to combining pet with 4dct to get a 4d petct scan for tumours that move with breathing. this study is divided into three cancer types; lung, lower oesophagus and pancreatic cancer. first the investigators are going to test the use of 4d petct in the radiotherapy planning of these tumours to see if it helps the doctor to identify the cancer. secondly, the investigators are going to see if the 4d petct helps to show areas within the cancer that are potentially more active. this might then allow us to target a higher dose to these areas, which could potentially improve the chance of controlling and curing the cancer. patients' standard treatment will not be altered by participating in the study.


Eligibility criteria:
inclusion criteria: * age ≥18 * who performance status 02 (appendix a) * histologically proven non small cell lung carcinoma, distal oesophageal carcinoma or pancreatic adenocarcinoma * clinical decision made to proceed with a course of radiotherapy of curative intent with or without concurrent chemotherapy * measurable primary tumour and/or locoregional metastatic lymph nodes on preradiotherapy imaging * able to provide fully informed written consent * able to lie flat for 1 hour * not be pregnant or breast feeding. female patients of childbearing potential must agree to use effective contraception, be surgically sterile, or be postmenopausal. exclusion criteria: 1. hypersensitivity to fluorine18 fludeoxyglucose (fdg) 2. hypersensitivity to iodinated contrast media 3. poorly controlled diabetes 4. acute renal failure or moderate renal impairment (estimated glomerular filtration rate \< 30 ml/min) 5. claustrophobia precluding imaging 6. uncontrolled pain 7. urinary incontinence 8. female patients must not be pregnant and if of child bearing age using adequate contraception 9. breast feeding 10. serious psychiatric comorbidity
aromatherapy for chemotherapy-induced nausea and vomiting (cinv)

Conditions: Chemotherapy-induced Nausea and Vomiting

Summary: the purpose of this study is to evaluate the use of aromatherapy to reduce nausea, vomiting, and the use of anti-emetic in cancer survivors undergoing moderate to highly emetogenic chemotherapy regimens.


Eligibility criteria:
inclusion criteria: 1. 18 years of age or older 2. able to read and speak english or spanish 3. able to and willing to give informed consent 4. currently undergoing moderate and high emetogenic chemotherapy (adjuvant or neoadjuvant) 5. receiving three or more remaining cycles of chemotherapy 6. symptoms of nausea or vomiting after the first chemotherapy infusion exclusion criteria: 1. unable or unwilling to give informed consent 2. sensitivity to essential oils\* 3. olfactory disorders 4. receiving chemotherapy for the first time 5. undergoing low emetogenic chemotherapy regimens 6. patients with hormone-sensitive cancers 7. timely request of treating provider
central-boost ablative radiation therapy for solid tumors (cbart)

Conditions: Pancreatic Cancer

Summary: in the case of large tumors or tumors closely adjacent to organs at risk, ablative doses offered by stereotactic body radiation therapy (sbrt) could not be delivered. therefore, a technique that could provide high radiation doses to tumors without increasing of risks of severe adverse effects is required.

regarding the advanced stage tumor, especially tumors with large volumes or closely adjacent to organs at risk, patients are not candidates for surgical resection. therefore, raduitherapy may be the optimal local therapy to ameliorate symptoms and be combined with systemic therapy, including chemotherapy, targeted therapy or immunotherapy. however, for those tumors, ablative doses could not be given due to large volumes and abutting to organs at risk. in order to solve the problem, spatially fractionated radiation therapy (sfrt) is used. in details, it was performed based on grid or lattice, which creates several cylindrical high-radiation-dose areas in tumors. nevertheless, the ablative dose areas are limited albeit with sfrt, which may not greatly improve tumor local. hence, we create an inner and complete inner gross tumor volume that would be delivered ablative radiation doses, which is named as central-boost ablative radiation therapy (cbart). we aim to investigate the efficacy and safety of cbart in large tumors or tumors adjacent to organs at risk.

Eligibility criteria:
inclusion criteria: * aged 18-75 years. * pathologically confirmed lung, liver, pancreas or retroperitoneal malignant tumor. * oligometastasis in the case of metastatic tumor * the shortest diameter ≥2cm or the distance from the tumor to the organs at risk less than 5mm * ecog of 0 to 1 point * no abnormality in blood routine test, liver and kidney function test and coagulation test (white blood cell count ≥4.0×10\^9/l, neutrophil count ≥2.0×10\^9, hemoglobin level ≥100g/l, platelet count ≥100×10\^9/l, alt and ast level \< 2.5 times the upper limit of normal, total bilirubin and creatinine level within the normal, international normalized ratio \<2) exclusion criteria: * history of radiotherapy for the lesion * history of tumor within 5 years * ecog ≥2 points * significant abnormality in blood routine test, liver and kidney function test and coagulation test * active inflammatory bowel disease in the case of pancreas or retroperitoneal tumor * gastrointestinal bleeding or perforation within 6 months in the case of pancreas or retroperitoneal tumor * infections required antibiotics * heart or respiratory insufficiency * pregnant or breastfeeding women

Keywords: pancreatic cancer stereotactic body radiation therapy inner gross tumor volume central boost ablative radiation dose
the potential biomark of serious psychosis:a prospective,case-controled study

Conditions: Other Immunological States or Disorders

Summary: patients suffer from serious psychosis may have variation in immunological factors,bdnf and mri.

patients suffer from schizophrenia and mood disorders may have variation in immunological factors(tnf-α,il-2,il-6,il-10,etc),bdnf and brain mri.

Eligibility criteria:
inclusion criteria: * diagnosis with schizophrenia , bipolar disorder or major depression by dsm-5 exclusion criteria: * unstable physical conditions
thoracic specimen registry

Conditions: Thoracic Diseases; Lung Cancer; Lung Transplant

Summary: the purpose of the registry will be to support ongoing research in the etiology, early diagnosis, clinical management, and prognosis of lung cancer and other cancers and diseases of the thorax by developing a complete repository of specimens from patients with thoracic disease including but not limited to suspected lung cancer, mediastinal and pleural tumors, lung transplants and from patients at a very high risk of developing other thoracic cancers or other thoracic diseases.

the primary objective of this proposal is to develop a thoracic specimen registry at mayo clinic. the purpose of the registry will be to support ongoing research in the etiology, early diagnosis, clinical management, and prognosis of lung cancer and other cancers and diseases of the thorax by developing a complete repository of specimens from patients with thoracic disease including but not limited to suspected lung cancer, mediastinal and pleural tumors, lung transplants and from patients at a very high risk of developing other thoracic cancers or other thoracic diseases. collected specimens will include peripheral blood, bronchoalveolar lavage (bal) fluid, pleural fluid, tissue (surgical resections \& biopsies) and touch prep samples. the specimens will be stored in a central location at mayo clinic and managed by the mayo clinic thoracic specimen registry steering committee. the registry will be a foundation for the development and implementation of research protocols and clinical trials that will enhance current knowledge of etiology and detection, discovery of new molecular and biochemical markers for screening, early diagnosis, and develop state-of-the-art therapeutic and preventive interventions for managing patients with, or at risk for, thoracic cancers or other thoracic diseases.

Eligibility criteria:
inclusion criteria: * subject must be \> 18 years of age * presumed or known or screening of thoracic diseases (which includes but not limited to the following: thoracic neoplasms (masses/nodules) malignant or benign, interstitial lung diseases (ild), chronic obstructive pulmonary disease (copd), thoracic infections, thoracic malignancies metastatic to other organs, other cancers metastatic to the thoracic cavity.
feasibility, acceptability and preliminary efficacy of the new iteration of the innovative smartphone-based care solution for women with breast cancer undergoing chemotherapy (icarebreast+): a pilot study research proposal

Conditions: Breast Cancer

Summary: the overall aim of the study is to evaluate the feasibility, acceptability and preliminary effects of the next iteration of icarebreast+, an innovative breast care e-support intervention programme, by refining existing contents and building new contents based on comprehensive assessment of breast cancer women's needs and preferences among breast cancer patients undergoing chemotherapy. the specific objectives of this study are: 1. to develop a new iteration of an innovative smartphone-based self-care solution for patients with breast cancer undergoing chemotherapy (icarebreast+); 2. to assess the feasibility and acceptability of icarebreast+; and 3. to explore the preliminary effects of icarebreast+ on the primary outcome of self-efficacy, and knowledge of breast cancer treatment, as well as secondary outcomes including anxiety, depression, health-related quality of life (hrqol), social support and satisfaction with oncologic care.

a two-group pilot randomized controlled trial with pretest and post-test will be conducted in a tertiary hospital in singapore. women with breast cancer requiring chemotherapy (n = 40) will be recruited and randomly allocated to the intervention group (receiving icarebreast+ and routine care) or the control group (routine care only). feasibility data (patient recruitment and attrition, usefulness, ease of use, strengths and weaknesses), as well as app quality data will be collected. health outcomes will be measured using validated instruments at baseline and immediately after the 2-month intervention.

Eligibility criteria:
inclusion criteria: women who: * are the age of 21 years old and above at the point of recruitment; * are diagnosed with stage 1-3 breast cancer; * will undergo chemotherapy first time (initiating or up to #4 cycles of chemo is acceptable); * can speak, read and write in english or mandarin; and * has access to and able to use smart phone. exclusion criteria: those who : * are with a history of or concurrent other cancer types; * have been suffering from psychiatric illness (e.g., schizophrenia), anxiety disorder or other mood disorder or impaired cognitive function; * have alcohol or substance abuse within the previous year; * are undergoing concurrent psychosocial interventions; and * have been in the bereavement period in the last 6 months * are in their pregnancy.

Keywords: breast cancer digital health mhealth mobile health psychosocial randomized controlled trial self-efficacy chemotherapy